Zymeworks Inc.
ZYME evidence brief
What we can confirm
- Market Cap:
- $1.95B
What it means
What to watch
Prepared research question
What matters most for ZYME—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ZYME
Zymeworks Inc. (ZYME) is a global biotechnology company that manages a portfolio of licensed healthcare assets and develops a pipeline of multifunctional biotherapeutics for cancer, inflammation, and autoimmune diseases, with a strategy focused on royalty growth, strategic acquisitions, and internal innovation [sec_mda · as of 2026-08-06].
Key risk: Sustained net losses
Market Cap
$1.95B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 clinical trials for Zymeworks Inc..
Zymeworks Inc. (ZYME) is a global biotechnology company that manages a portfolio of licensed healthcare assets and develops a pipeline of multifunctional biotherapeutics for cancer, inflammation, and autoimmune diseases, with a strategy focused on royalty growth, strategic acquisitions, and internal innovation [sec_mda · as of 2026-08-06].
- Cash & equivalents of $179.4M as of 2026-06-30 [sec].
- Total revenue of $4.6M and net income of -$45.0M for the period ending 2026-06-30 [sec].
- Shareholders' equity of $80.4M as of 2026-06-30 [sec].
- Royalty revenue from Jazz and BeOne was $1.8M in the three months ended June 30, 2026, driven primarily by net product sales of Ziihera [sec_mda · as of 2026-08-06].
- Phase 1 trials initiated for ZW171 (mesothelin-targeting) and ZW191 (folate receptor alpha ADC) in 2024 [catalyst].
What works
- Diversified revenue stream through royalty and milestone payments from commercial partners, with $1.8M in quarterly royalty revenue from Ziihera sales [sec_mda · as of 2026-08-06].
- Strong cash position of $179.4M provides runway for R&D and strategic acquisitions [sec].
- Proprietary MSAT and ADC technology platforms enable development of novel multifunctional therapeutics [sec_mda · as of 2026-08-06].
- Risk-sharing partnerships reduce reliance on internal capital for late-stage development [sec_mda · as of 2026-08-06].
What to weigh
- Net income of -$45.0M indicates ongoing operating losses, with the company noting it will not be net income positive on a regular basis in the short term [sec_mda · as of 2026-05-07].
- Dependence on partner-driven milestones and royalties creates uncertainty in future cash flows [sec_mda · as of 2026-08-06].
- Inflationary pressures could adversely impact financial results [sec_mda · as of 2026-05-07].
- Most pipeline candidates are in early clinical stages (Phase 1), with no near-term revenue from internal programs [catalyst].
From the filings
Quoted directly from source documents.
Quarterly royalty revenue from Ziihera
“Our royalty revenue from Jazz and BeOne was $1.8 million in the three months ended June 30, 2026”
SEC MD&A · August 6, 2026
Company strategy focuses on royalty growth and strategic acquisitions
“Our strategy is focused on compounding long-term stockholder value through a combination of royalty growth, strategic acquisitions, and internal innovation”
SEC MD&A · August 6, 2026
Catalyst timeline
- 2024-09-30 · Phase 1 start for ZW171 — Phase 1 open-label study of ZW171 in advanced ovarian cancer, NSCLC, and other mesothelin-expressing cancers.
- 2024-10-30 · Phase 1 start for ZW191 — Phase 1 open-label study of ZW191, a folate receptor alpha ADC, in advanced solid tumors.
- 2026-08-06 · Earnings: Zymeworks to Report Second Quarter 2026 Financial Results — Company will report its second quarter 2026 financial results after market close.
Risks & what to watch (4)›
Key risks
- Sustained net losses — Net income of -$45.0M as of 2026-06-30; company expects not to be regularly net income positive in the short term [sec_mda · as of 2026-05-07].
- Dependence on partners
- Early-stage pipeline
- Inflationary pressure
What to watch
- Second quarter 2026 financial results to be reported on August 6, 2026 [catalyst].
- Second interim overall survival analysis for HERIZON-GEA-01 trial expected in mid-2026 [sec_mda · as of 2026-05-07].
- Phase 1b clinical data for pasritamig expected in second half of 2026 [sec_mda · as of 2026-08-06].
- Regulatory submission for ZW1528 anticipated [sec_mda · as of 2026-08-06].
Sources: Catalysts · News · Pipeline · SEC MD&A · Generated October 7, 2026 · How we verify sources →
Run Zymeworks Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Zymeworks Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
211
Total value held
$1.75B
| Holder | Shares | Value |
|---|---|---|
| ecor1 capital, llc | 22,970,388 | $575.2M |
| rubric capital management lp | 7,000,000 | $175.3M |
| blackrock, inc. | 4,553,888 | $114.0M |
| bvf inc/il | 3,734,142 | $93.5M |
| perceptive advisors llc | 3,510,078 | $87.9M |
| morgan stanley | 2,480,568 | $62.1M |
| bnp paribas asset management holding s.a. | 1,908,039 | $47.8M |
| vanguard capital management llc | 1,705,580 | $42.7M |
| citadel advisors llc | 1,150,018 | $28.8M |
| dimensional fund advisors lp | 1,139,135 | $28.5M |
Showing top 10 of 211 institutional holders of Zymeworks Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 9.4%
- Days to cover
- 7.6
- Shares short
- 4,648,225
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ZYME short interestGovernance
Frequently asked questions
What is the AI investment thesis for Zymeworks Inc.?
Zymeworks Inc. (ZYME) is a global biotechnology company that manages a portfolio of licensed healthcare assets and develops a pipeline of multifunctional biotherapeutics for cancer, inflammation, and autoimmune diseases, with a strategy focused on royalty growth, strategic acquisitions, and internal innovation [sec_mda · as of 2026-08-06].
Who is the CEO of Zymeworks Inc.?
Mr. Kenneth H. Galbraith C.A. is the chief executive officer of Zymeworks Inc. (ZYME).
Where is Zymeworks Inc. headquartered?
Zymeworks Inc. (ZYME) is headquartered in Middletown, DE, United States.
What therapeutic areas does Zymeworks Inc. focus on?
Zymeworks Inc. develops therapies across Oncology, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.